Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 2/20 | 0.47 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 6/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19949266 | 0.84 | ATR (0.43) | ATRAAK1ALDH1A1PIK3CA | |
| SCHEMBL19949449 | 0.82 | ATR (0.45) | ATRAAK1CYP3A4TSHRCYP2C19 | |
| SCHEMBL18108807 | 0.76 | ALDH1A1 (0.41) | AAK1CYP3A4TSHRCYP2C19ALDH1A1 | |
| SCHEMBL19949458 | 0.75 | GAA (0.37) | AAK1ALDH1A1PIK3CA | |
| SCHEMBL4929750 | 0.74 | TSHR (0.40) | ATRAAK1CYP3A4TSHRCYP2C19 | |
| SCHEMBL2463873 | 0.73 | ALDH1A1 (0.40) | AAK1CYP3A4TSHRCYP2C19ALDH1A1 | |
| SCHEMBL19949270 | 0.72 | ATR (0.41) | ATRTSHRALDH1A1LRRK2PIK3CA | |
| SCHEMBL4929760 | 0.69 | TSHR (0.40) | AAK1CYP3A4TSHRCYP2C19ALDH1A1 | |
| SCHEMBL16176806 | 0.68 | ALDH1A1 (0.41) | AAK1CYP3A4TSHRCYP2C19ALDH1A1 | |
| SCHEMBL5130605 | 0.68 | HRH3 (0.43) | CYP3A4TSHRCYP2C19ALDH1A1LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10538491-B2 | 4,5-substituted picolinamide and picolinonitrile metabotropic glutamate receptor 2 negative allosteric modulators | VANDERBILT UNIVERSITY (US) | 2020-01-21 | — | — | US | disclosed |
| US-20180072674-A1 | NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 | VANDERBILT UNIVERSITY (US) | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10538491-B2 | 4,5-substituted picolinamide and picolinonitrile metabotropic glutamate receptor 2 negative allosteric modulators | GRM2, GRIA2, GRIN2A | ATR 2346/4885AAK1 523/4885CYP3A4 1758/4885 |
| US-20180072674-A1 | NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 | GRM2, GRM1, GRIN2A | ATR 621/4885AAK1 227/4885CYP3A4 4385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.